by admin | Jan 18, 2019 | Bernie Siegel’s WORLD STEM CELL SUMMIT BLOG, News and Opinions
MIAMI, Jan. 18, 2019 /PRNewswire/ — Longeveron LLC, a biopharmaceutical company that develops cellular therapies for aging-related diseases, will play a prominent role when leading experts gather in Miami for the 2019 World Stem Cell Summit, Jan. 22-25 at the...
by admin | Jan 18, 2019 | Bernie Siegel’s WORLD STEM CELL SUMMIT BLOG, News and Opinions
EXTON, Pa., Jan. 16, 2019 (GLOBE NEWSWIRE) — Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that John Maslowski, President and...
by admin | Jan 18, 2019 | Bernie Siegel’s WORLD STEM CELL SUMMIT BLOG, News and Opinions
Nighttime partnering cocktail event Daytime seminars, meetings and trainings #WSCS2019 and #PLW2019 January 22-25, 2019, Hyatt Regency Miami Miami, FL, Jan. 17, 2019 (GLOBE NEWSWIRE) — The co-located Phacilitate Leaders World and World Stem Cell Summit (WSCS)...
![Emily Whitehead Foundation and Phacilitate to Hold Yacht Party Fundraiser at Phacilitate Leaders World in Miami]()
by admin | Jan 18, 2019 | Bernie Siegel’s WORLD STEM CELL SUMMIT BLOG, News and Opinions
PHILIPSBURG, Pa. (Nov. 20, 2018) – In an effort to bring more awareness to pediatric cancer immunotherapy research, the Emily Whitehead Foundationand London-based Phacilitate are joining together to hold a one of a kind fundraising event in Miami, Florida on January...
by admin | Jan 17, 2019 | Bernie Siegel’s WORLD STEM CELL SUMMIT BLOG, News and Opinions, Video
FREEHOLD, N.J., Jan 15, 2019 (GLOBE NEWSWIRE via COMTEX) — Avalon GloboCare Corp. AVCO, +0.00% a leading global developer of cell-based technologies, announced today that its President and Chief Executive Officer, David Jin, M.D., Ph.D., will chair and speak at...
by admin | Jan 17, 2019 | Bernie Siegel’s WORLD STEM CELL SUMMIT BLOG, News and Opinions
HOUSTON, Jan. 17, 2019 /PRNewswire/ — Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid...
